Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more
Capricor Therapeutics Inc (CAPR) - Net Assets
Latest net assets as of September 2025: $83.87 Million USD
Based on the latest financial reports, Capricor Therapeutics Inc (CAPR) has net assets worth $83.87 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($126.44 Million) and total liabilities ($42.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $83.87 Million |
| % of Total Assets | 66.33% |
| Annual Growth Rate | N/A |
| 5-Year Change | 415.83% |
| 10-Year Change | N/A |
| Growth Volatility | 214.27 |
Capricor Therapeutics Inc - Net Assets Trend (1999–2024)
This chart illustrates how Capricor Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Capricor Therapeutics Inc (1999–2024)
The table below shows the annual net assets of Capricor Therapeutics Inc from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $145.46 Million | +543.60% |
| 2023-12-31 | $22.60 Million | +91.76% |
| 2022-12-31 | $11.79 Million | -62.43% |
| 2021-12-31 | $31.37 Million | +11.23% |
| 2020-12-31 | $28.20 Million | +312.31% |
| 2019-12-31 | $6.84 Million | +48.18% |
| 2018-12-31 | $4.62 Million | -58.89% |
| 2017-12-31 | $11.23 Million | +380.45% |
| 2016-12-31 | $-4.00 Million | -287.99% |
| 2015-12-31 | $-1.03 Million | +83.49% |
| 2014-12-31 | $-6.25 Million | -1068.24% |
| 2013-12-31 | $-534.88K | -110.93% |
| 2012-12-31 | $4.89 Million | +489.18% |
| 2011-12-31 | $830.72K | -68.01% |
| 2010-12-31 | $2.60 Million | -12.92% |
| 2009-12-31 | $2.98 Million | -41.57% |
| 2008-12-31 | $5.10 Million | -66.42% |
| 2007-12-31 | $15.20 Million | +11740.50% |
| 2006-12-31 | $-130.58K | -68.22% |
| 2005-12-31 | $-77.62K | -32.10% |
| 2004-12-31 | $-58.76K | -44.43% |
| 2003-12-31 | $-40.69K | -65.87% |
| 2002-12-31 | $-24.53K | -174.31% |
| 2001-12-31 | $-8.94K | -166.93% |
| 2000-12-31 | $13.36K | +2265.48% |
| 1999-12-31 | $-617.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Capricor Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19983382200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $45.58K | 0.03% |
| Other Comprehensive Income | $1.03 Million | 0.71% |
| Other Components | $344.22 Million | 236.64% |
| Total Equity | $145.46 Million | 100.00% |
Capricor Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Capricor Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sunwave Communications Co Ltd
SHE:002115
|
$1.17 Billion |
|
Xinfengming Group Co Ltd
SHG:603225
|
$1.17 Billion |
|
Rush Street Interactive Inc
NYSE:RSI
|
$1.17 Billion |
|
Ruijie Networks Co. Ltd. A
SHE:301165
|
$1.17 Billion |
|
Zhongshan Public Utilities Group Co Ltd
SHE:000685
|
$1.17 Billion |
|
Outokumpu Oyj
PINK:OUTFF
|
$1.17 Billion |
|
Pharma Mar S.A.
MC:PHM
|
$1.17 Billion |
|
UMH Properties Inc
NYSE:UMH
|
$1.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Capricor Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,601,467 to 145,462,336, a change of 122,860,869 (543.6%).
- Net loss of 40,467,186 reduced equity.
- New share issuances of 152,321,576 increased equity.
- Other comprehensive income increased equity by 791,143.
- Other factors increased equity by 10,215,336.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-40.47 Million | -27.82% |
| Share Issuances | $152.32 Million | +104.72% |
| Other Comprehensive Income | $791.14K | +0.54% |
| Other Changes | $10.22 Million | +7.02% |
| Total Change | $- | 543.60% |
Book Value vs Market Value Analysis
This analysis compares Capricor Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $-0.45 | $30.90 | x |
| 2000-12-31 | $9.72 | $30.90 | x |
| 2001-12-31 | $-5.92 | $30.90 | x |
| 2002-12-31 | $-16.24 | $30.90 | x |
| 2003-12-31 | $-26.94 | $30.90 | x |
| 2004-12-31 | $-38.92 | $30.90 | x |
| 2005-12-31 | $-51.41 | $30.90 | x |
| 2006-12-31 | $-4.89 | $30.90 | x |
| 2007-12-31 | $448.59 | $30.90 | x |
| 2008-12-31 | $105.77 | $30.90 | x |
| 2009-12-31 | $58.55 | $30.90 | x |
| 2010-12-31 | $40.36 | $30.90 | x |
| 2011-12-31 | $11.13 | $30.90 | x |
| 2012-12-31 | $57.99 | $30.90 | x |
| 2013-12-31 | $-0.51 | $30.90 | x |
| 2014-12-31 | $-5.34 | $30.90 | x |
| 2015-12-31 | $-0.65 | $30.90 | x |
| 2016-12-31 | $-2.16 | $30.90 | x |
| 2017-12-31 | $4.19 | $30.90 | x |
| 2018-12-31 | $1.57 | $30.90 | x |
| 2019-12-31 | $1.84 | $30.90 | x |
| 2020-12-31 | $1.81 | $30.90 | x |
| 2021-12-31 | $1.36 | $30.90 | x |
| 2022-12-31 | $0.48 | $30.90 | x |
| 2023-12-31 | $0.84 | $30.90 | x |
| 2024-12-31 | $4.13 | $30.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Capricor Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -181.71%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.17x
- Recent ROE (-27.82%) is above the historical average (-100.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 0.00% | 0.00% | 0.00x | 0.00x | $-138.30 |
| 2000 | -273.35% | 0.00% | 0.00x | 1.07x | $-37.86K |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.41K |
| 2002 | 0.00% | -135.73% | 459.36x | 0.00x | $-13.13K |
| 2003 | 0.00% | -739.79% | 2.02x | 0.00x | $-12.09K |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.20K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.10K |
| 2006 | 0.00% | -16.11% | 90.68x | 0.00x | $-47.88K |
| 2007 | -67.78% | -10160.75% | 0.01x | 1.12x | $-11.82 Million |
| 2008 | -257.31% | 0.00% | 0.00x | 1.26x | $-13.64 Million |
| 2009 | -263.97% | 0.00% | 0.00x | 1.21x | $-8.17 Million |
| 2010 | -232.24% | 0.00% | 0.00x | 1.41x | $-6.29 Million |
| 2011 | -588.04% | -360.52% | 0.99x | 1.65x | $-4.97 Million |
| 2012 | -38.68% | -968.29% | 0.04x | 1.11x | $-2.38 Million |
| 2013 | 0.00% | -1766.97% | 0.09x | 0.00x | $-8.84 Million |
| 2014 | 0.00% | -149.20% | 0.31x | 0.00x | $-5.59 Million |
| 2015 | 0.00% | -340.50% | 0.23x | 0.00x | $-12.75 Million |
| 2016 | 0.00% | -589.53% | 0.17x | 0.00x | $-18.41 Million |
| 2017 | 21.66% | 177.84% | 0.08x | 1.45x | $1.31 Million |
| 2018 | -329.13% | -908.91% | 0.18x | 2.00x | $-15.65 Million |
| 2019 | -111.73% | -760.36% | 0.09x | 1.62x | $-8.33 Million |
| 2020 | -48.43% | -4401.94% | 0.01x | 1.23x | $-16.48 Million |
| 2021 | -63.83% | -8175.86% | 0.01x | 1.32x | $-23.16 Million |
| 2022 | -246.22% | -1137.37% | 0.05x | 4.25x | $-30.20 Million |
| 2023 | -98.61% | -88.52% | 0.43x | 2.60x | $-24.55 Million |
| 2024 | -27.82% | -181.71% | 0.13x | 1.17x | $-55.01 Million |
Industry Comparison
This section compares Capricor Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Capricor Therapeutics Inc (CAPR) | $83.87 Million | 0.00% | 0.51x | $1.17 Billion |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |